OVERVIEW
A Cost-Effectiveness Model (CEM) compares the costs and outcomes of a new therapy against one or more comparators, typically expressed as an incremental cost per QALY gained. CEMs are the cornerstone of HTA submissions to NICE, SMC, AWMSG, G-BA, HAS, CADTH, and other major bodies.
WHEN TO USE THIS MODEL
Is this the right model for you?
- Preparing a Technology Appraisal submission to NICE or SMC
- Building the economic evidence base for international HTA submissions
- Informing pricing and reimbursement strategy ahead of launch
- Exploring value scenarios and willingness-to-pay thresholds
- Adapting a global model for local HTA requirements
WHAT WE DELIVER
What's included
Model selection
decision tree, Markov cohort, partition survival, or discrete event simulation depending on indication and available data
Clinical inputs
transition probabilities, survival curves, and relative treatment effects from trials or network meta-analysis
Health state utilities
mapped from EQ-5D or published sources
Cost inputs
NHS reference costs, PSSRU, BNF, and local equivalents for international submissions
Incremental cost-effectiveness ratio (ICER) and cost-effectiveness plane
Probabilistic sensitivity analysis and cost-effectiveness acceptability curves
Full technical report, model file, and HTA-ready documentation
PRICING
Fee tiers
TIER
FEE
TIMELINE
Decision Tree
Acute or short-term conditions, single market submission
£15,000–25,000
6–8 weeks
Markov Model
Chronic conditions, single HTA submission
£30,000–55,000
10–16 weeks
Partition Survival Model
Oncology, single HTA submission
£35,000–60,000
12–16 weeks
Global CEM
Core model with up to 3 HTA adaptations
£65,000–110,000
16–24 weeks
All fees are fixed price. Scope, deliverables, and timeline are agreed before work begins. Additional market adaptations available — contact us for a tailored quote.